Cell Therapy Biomanufacturing Market

Market Overview

The Cell Therapy Biomanufacturing market was valued at $1.6 billion in 2016 and is projected to reach $3.2 billion by 2028.

As the demand for cell therapies grows, so does the need for efficient and reliable manufacturing processes. The cell therapy biomanufacturing market is expected to grow rapidly in the coming years, as more and more companies invest in developing this technology.

Cell therapy involves using living cells to treat or cure a disease or condition. In order to mass-produce these cells, they must be grown in a controlled environment outside of the body. This process is known as cell culture.

There are two main types of cell culture: adherent and suspension. Adherent cultures attach the cells to a surface, while suspension cultures keep the cells suspended in a liquid media. Each method has its own advantages and disadvantages.

The most common type of cell used in cell therapy is the mesenchymal stem cell (MSC). MSCs can be derived from many different sources, including bone marrow, fat tissue, and cord blood. They have the ability to differentiate into many different types of cells, making them ideal for treating a wide variety of diseases and conditions.

Current methods of manufacturing MSCs are time-consuming and expensive. However, new technologies are being developed that could significantly improve the efficiency and cost-effectiveness of MSC production.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player.

They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

  • Bone Therapeutics S.A., 
  • Caladrius Biosciences, Inc., 
  • Iovance Biotherapeutics, Inc., 
  • Lonza Group AG, 
  • Merck KGaA, 
  • Novartis AG, 
  • Regen BioPharma, Inc., 
  • Regeneus Ltd., 
  • The Bristol-Myers Squibb Company (BMS)

Get Sample Copy Of This Report@ https://www.datalibraryresearch.com/sample-request/?id=3147&utm_source=analyzermarket&utm_medium=34

Segmentation Analysis

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.

By Type:

• Consumables

• Equipment

• Systems & Software

By Cell Type

• T-cell

• Stem Cell

• Other Cell

By Process

• Cell Processing

• Cell Preservation, Distribution, and Handling

• Process Monitoring and Quality Control

By Application:

• Biopharmaceutical & Biotechnology Companies and CROs

• Research Institutes and Cell Banks


As the global population continues to age, the incidence of chronic disease is on the rise. This is one of the key drivers of the cell therapy biomanufacturing market. Chronic diseases such as diabetes, cancer, and heart disease are becoming more prevalent, and cell therapies offer a potential treatment option for these conditions.

In addition, the increasing affordability of cell therapies is another driver of market growth. As cell therapy technology advances and manufacturing processes become more efficient, the cost of these treatments is decreasing. This makes them more accessible to a wider range of patients.

Finally, the growing awareness of the potential benefits of cell therapy is also driving the market growth. More people are becoming aware of the potential for these treatments to improve their health and quality of life. As word spreads about the benefits of cell therapy, more people will be likely to seek out these treatments.


There are several potential obstacles to the widespread adoption of cell therapy biomanufacturing, including the high cost of production, the need for specialized manufacturing facilities, and the lack of regulatory clarity.

The high cost of cell therapy biomanufacturing is a significant barrier to market growth. Cell therapies are complex products that require specialized facilities and equipment. The cost of building and maintaining a cell therapy manufacturing facility is significant, and there are few companies with the experience and expertise to manufacture these products.

The lack of regulatory clarity is another obstacle to market growth. Cell therapies are a new and rapidly evolving field, and the regulatory landscape is still evolving. There are no clear guidelines for the manufacture or marketing of cell therapies, which makes it difficult for companies to invest in this area.

Finally, the need for specialized manufacturing facilities limits the number of companies that can enter the market. Cell therapy biomanufacturing is a complex process that requires specific expertise and knowledge. Few companies have the necessary experience and resources to establish themselves as manufacturers of these products.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the cell therapy biomanufacturing market. The production of cell therapies has been disrupted due to the closure of manufacturing facilities and restriction on international trade.

Regional Analysis

North America is expected to account for the largest share of the cell therapy biomanufacturing market in 2020. The large share of this regional market can be attributed to the rising incidence of cancer and chronic diseases, government support for cell therapy research, and the presence of a large number of contract manufacturing organizations (CMOs) in the region. 

The Asia Pacific region is expected to grow at the highest CAGR during the forecast period due to the increasing number of clinical trials being conducted in China and Japan, government initiatives to support cell therapy research and the growing number of CMOs in the region.

Table of Content

1. Introduction

2. Executive Summary

3. Market Dynamics

4. Key Insights

5. Global Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

6. North America Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

7. Latin America Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

8. Europe Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

9. Asia Pacific Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

10. Middle East & Africa Cell Therapy Biomanufacturing Market Analysis (USD Billion), Insights and Forecast, 2016-2027

11. Competitive Analysis

For Enquiry before buying report @  www.datalibraryresearch.com/enquiry/?id=3147&utm_source=analyzermarket&utm_medium=34